Our Vision

Our vision is to improve patient care using integrated approaches involving laboratory models, mathematical models and machine-learning/Al methods to reduce time to bringing new therapies to market and to optimize treatments for patients after regulatory approval.

Our tools include quantitative wet laboratory models made of human-tissue, non-linear dynamical systems, and non-linear mathematical models, which we wrote from scratch and coded, for drug discovery development.

Our physician dominated team uses clinical and pathophysiologic know-how, the mathematics of topology and morphism mapping and category theory, to map disease response from the preclinical models to patients, so that readouts in our preclinical models will give precise rates of responses expected in patients, not just in terms of how many patients respond to therapy, but how fast, and the optimal duration of such therapy, and the doses to minimize failure and resistance to therapy. Thus, we can forecast clinical responses in early preclinical development, and then design adaptive clinical trials de novo, including the biomarkers of therapeutic response, duration of therapy, thereby de-risking time (decades), money (millions), and clinical trial patients’ lives (unquantifiable).

We also design combination therapy regimens using factorial design to find best companion drugs and doses for therapeutics.

Our motto summarizes it all. Quantify. Predict. Cure.

Meet Our Leadership Team

Tawanda Gumbo, M.D.

President & CEO, Founder

 

View Bio

Tawanda Gumbo, MD, is a physician scientist, rising to the rank of Professor of Medicine. Medical School was at the University of Zimbabwe, Residency in Internal Medicine at Case Western Reserve University, and Fellowship in Infectious Diseases at the Cleveland Clinic, in Cleveland, Ohio.

Dr. Gumbo developed several preclinical and clinical laboratory models for fungal, parasitic, bacterial and viral infections, the human immune system, and cancer. He has also developed several mathematical models for translation from the laboratory to patients in the area of therapeutics and quantitative translational pharmacology, and for characterizing disease progression and the immune system in patients based on next generation sequencing and other ‘omics.

He has received research funding for decades from the US NIH, and other private-public funders. Dr. Gumbo is the recipient of numerous awards. His research work has been used to identify optimal doses of the three currently licensed antifungal drugs called echinocandins, anti-TB compounds by the WHO Global TB Program and by national TB programs in numerous countries, the design of new anti-TB drug regimens for children and adults, treatment of non-tuberculous mycobacteria, and together with his team recently identified and characterized safe inhibitors of the fundamental physiologic pathway, sonic hedgehog signaling, and the role of inhibitory immune checkpoints in TB.

He holds several patents for diagnostics, and for monoclonal antibodies that bind to FCER1. Dr. Gumbo is also a published poet and novelist. He also writes the introduction chapter to anti-infective therapy chapter, and the treatment of mycobacterial infections chapter in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, referred to as the “Bible of pharmacology. He has authored about 200 scientific publications on PubMed: VIEW HERE

David Howe, PhD.

Vice President & CSO / COO

 

View Bio

Dr. David Howe is an industry veteran with more than 25 years experience in the pharmaceutical industry. Dr. Howe received his PhD in Medicinal Chemistry from the University of Michigan, MSc in Medicinal Chemistry from the University of Michigan and a BSE in Aerospace Engineering from the University of Michigan.

His doctoral research involved the investigation of the enzymatic mechanisms of novel biological targets to design new antibacterials for gram-negative bacteria. Dr. Howe has experience in both drug discovery and drug development covering drug substance characterization and analytical development for GLP activities formulation development and characterization, drug metabolism, bioanalytics, metabolite identification, pharmacokinetics, toxicokinetics and model based drug development (pharmacokinetics/pharmacodynamices).

Dr. Howe has held senior scientific and management positions at Pfizer, Vertex Pharmaceuticals and AstraZeneca. In these positions, he participated drug discovery and development teams supporting drug metabolism, pharmacokinetics, and PK/PD for antibacterial programs and various disease areas and led the functions of drug metabolism (ADME), pharmacokinetics, pharmacokinetic/pharmacodynamics and bioanalysis. He has a number of successful drugs in portfolio that he has contributed to including Lyrica (Pregabalin), Kalydeco, Telzir & Incivek. In addition to his experience in discovery and non-clinical development Dr. Howe has experience in the design and support of clinical trials through Phase III for antibacterials.

Meet Our Scientific Leadership Team

Shruti Athale, PhD.

Associate Director/Team Lead, Hollow Fiber & Experimental Therapeutics Laboratories

 

View Bio

  1. PhD in immunology
  2. Dr. Athale has worked on immunological aspects of various infectious diseases like vaccinia virus, influenza vaccine and TB.
  3. With Dr. Gumbo was instrumental in development of hollow fiber system using peripheral blood monocytes (PBMCs) to study the role of innate / adaptive immunity as well as the role of different immune checkpoints
  4. Study of early immune response induced by inactivate influenza vaccines in vitro and in vivo
  5. Developed a strategy that is safe and effective against smallpox by using modified Ankara virus (MVA) in mouse models and (iv) Investigate, the role of neutrophils in systemic lupus erythematosus (SLE).
  6. She has 15 years of experience in developing disease models. She had developed mouse models for vaccinia virus infection/ challenge, developed chimeric mouse models as well as mouse model of arthritis.
  7. Expertise in immunology, specifically using various immunological assays like immunophenotyping, antibody biding assays, cell sorting and experience in several disease models

Moti Chapagain, M.D., PhD.

Director, Hollow Fiber & Experimental Therapeutics Laboratories

 

View Bio

  1. MD, PhD; Physician and bench scientist
  2. Extensive training and experience in work with both DNA and RNA viruses and parasites
  3. Has published dozens of seminal papers on epidemiology, molecular pathogenesis, diagnosis and treatment of important human viruses including human polyomavirus JC (JCV), West-Nile virus (WNV) and dengue virus.
  4. Explored role of serotonin receptor blocker risperidone against JCV and roles of minocycline and tumor necrosis factor a receptor 2 in WNV and is expert in virus culture, characterization and quantification
  5. Expert in laboratory hollow fiber models of tuberculosis, Mycobacterium avium-complex, Mycobacterium abscessus, and Mycobacterium kansasii

Hui-Chen Foreman, PhD.

Head & Director, Molecular Biology & Technology Development Laboratory

 

View Bio

  1. Education: Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago.
  2. Formerly Senior Level Scientist at the American Type Culture Collection [ATCC] &  Principal Investigator of a business development opportunities grant and a CDC contract
  3. Senior Research Associate, Liaison & Project Manager at Stony Brook University where she oversaw the scientific exchange in industrial collaboration with Theragnostic Technologies Inc.,
  4. Pioneering the establishment and feasibility of gene delivery to mammalian cells via graphene.
  5. Established proof of concept that CRISPR-Cas9 can specifically target virus genome editing and impair virus DNA replication
  6.  Crystallography to identify STAT3 nuclear localization signal.
  7. Expert in B-cell and T-cell sequencing, as well as monoclonal antibody sequencing.
  8. Patents for genetic engineering of microbes.

David Howe, PhD.

 

View Bio

  1. PhD in Medicinal Chemistry, an MSc in Medicinal Chemistry, and a BSc in Aerospace Engineering
  2. Over 25 years experience in both drug discovery and drug development, including at companies such as Vertex Pharmaceuticals, Pfizer, AstraZeneca Tanabe Research and LuminaCare Solutions, a mixture of startup, small, medium, and large biotech and pharma companies.
  3. Helped develop a number of successful drugs in his portfolio, including Lyrica (Pregabalin), Kalydeco, Telzir and Incivek.
  4. Developed diagnostics at LuminaCare Solutions
  5. Special modeling skills in pharmacometrics, modeling and simulations
  6. Special modeling skills Monte Carlo simulations expertise
  7. Special modeling and simulations to develop biomarkers
  8. Advanced Quantitative structure-activity relationship (QSAR) modeling and simulations
  9. Standard PK/PD modeling

Jotam Pasipanodya, M.D., DrPH

 

View Bio

  1. Clinical epidemiologist; physician scientist with quantitative skills in pharmacometrics, including machine-learning approaches applied to decision- and implementation sciences; clinical translation across global health
  2. Developed concepts of concentration-dependent antagonism/synergism using machine-learning algorithms for interaction detection, feature-selection and rule ensembles
  3. Developed and pioneered approaches for incorporating machine-learning methods in clinical translations, decision-and implementation sciences
  4. Use non-parametric adaptive grid (NPAG) to identify factors driving pharmacokinetic (PK) and pharmacodynamic (PD) variability across heterogenous patient groups
  5. Pioneered the use of machine learning methods, such as MARS with stochastic gradient boosting, as means for more efficient covariate selection during pop PK/PD modeling
  6. Recently, has been applying Langevin equations to identify the criticality signatures of dynamical systems to explain emergent properties, such as drug resistance or abhorrent lung damage.
  7. Has built integrated mathematical models for estimating therapy duration and time-to-cure using bacterial kill slopes, pop PK/PD and optimal multi-drug regimen selection.

 

Praedicare Africa Team

 

View Bio

Our Departments

Quality Control & Quality Assurance

Pharmaceutical Chemistry, Manufacturing & Controls

Molecular Biology & Technology Development Lab

Hollow Fiber System & Experimental Therapeutics Labs

Quantitative Preclinical & Clinical Sciences

Clinical Trials: FIH, Phase I-IV

Data Protection Security

Business Development & Partnerships

Business Manager

Interested in learning more?

Contact Us Today